Praxis reports $470M cash, NDA plans for ulixacaltamide in 2025, and UCB option exercise for KCNT1

Praxis Precision Medicines, Inc.

Cash, cash equivalents and marketable securities ~$470M at Dec 31, 2024; runway into 2028.
Interim analysis of Essential3 Study 1 for ulixacaltamide in essential tremor expected Q1 2025; NDA filing planned for 2025.
UCB exercised option to license KCNT1 small molecule; Praxis eligible for up to ~$100M milestones plus tiered royalties.
RADIANT (vormatrigine) topline in H1 2025; POWER1 (vormatrigine) topline by year-end 2025.
EMBOLD cohort 2 for relutrigine on track with NDA filing expected in 2026; third RPDD received for Dravet Syndrome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.